CN128

DRUG2 trials

Sponsors

Hangzhou Zede Pharma-Tech Co., Ltd., Professor Yongping Yu

Conditions

Iron Overload Iron Overload Iron Chelating AgentsThalassemia

Phase 1

An open-label, single center and single dose study to assess safety tolerability and pharmacokinetics of CN128 in healthy volunteers

Active, not recruitingTCTR20161110001

Professor Yongping YuIron Overload Iron Overload Iron Chelating Agents

Start: 2017-02-01Target: 44Updated: 2026-08-03

Clinical Study of CN128 in Thalassemia Patients

CompletedNCT03673085

Hangzhou Zede Pharma-Tech Co., Ltd.Thalassemia

Start: 2018-01-05End: 2019-12-17Updated: 2019-12-19